Our impact

Read case studies where we have partnered with clients in each of our four key mission areas.

Price right

How leveraging a ‘glocal’ approach supported the assessment of the pricing and reimbursement potential of a breakthrough orphan drug in China

How carefully selecting proximity indicators for meaningful analogue analysis helped to redefine the pricing strategy for a larger target population

How a fast, agile, and robust price triangulation across multiple rare blood disorders supported an asset indication prioritization strategy

How re-shaping an assets early value narrative towards the most impactful clinical scenarios streamlined its potential target indications and led to the next wave of funding

How a deep-dive analysis of pricing analogues informed the pricing strategy of a breakthrough advanced medicinal product in prostate cancer

How a deep understanding of the French IO landscape allowed for the development of core pricing scenarios to inform a client’s decision framework

How creating a unified vision and comprehensive framework for Real-World Evidence (RWE) supported seamless execution of RWE projects

How assessing the pricing and reimbursement risks associated with a product withdrawal supported the action steps to take in key Central and Eastern EU markets

How combining qualitative insights with survey outputs enabled deep understanding of payers’ preferences of the value a phase 3b multiple comparator study will bring in drug-resistant epilepsy

How a DELPHI survey informed the key inputs of a health economic model to support the launch of a breakthrough specialty product

How providing executive summaries of key diabetes studies & publications supported development of key marketing messages & promotional materials

How building a step by step market access strategy created a pricing and value roadmap for a specialty product in a highly competitive and genericized market

How developing an early payer value story and value messages supported a differentiated offer within neurology, covering multiple possible scenarios at global and regional levels

How developing a HTA and pricing framework for orphan drugs across EU5 can help optimize portfolio expansion

How primary research of payers’ data needs and decision-making processes guided global market access activities

How focusing on the operational elements of pricing strategy supported in-country teams to strengthen their approach to pricing incremental innovation

How fostering close communications to prioritize key market access activities, ensured the timely delivery of optimized value materials for specialty assets

How a comprehensive review of the payer landscape is being used to support the development of a novel gene therapy

What we do

Tailored solutions for today’s toughest market access challenges, helping you to prepare for tomorrow’s value-based healthcare.

Who we are

We are on a mission to help you to create superior value and optimise healthcare worldwide

Get started with Inbeeo and realise the true value of your assets.

Menu

Our impact

Menu

Our impact

Price right

How leveraging a ‘glocal’ approach supported the assessment of the pricing and reimbursement potential of a breakthrough orphan drug in China

How carefully selecting proximity indicators for meaningful analogue analysis helped to redefine the pricing strategy for a larger target population

How a fast, agile, and robust price triangulation across multiple rare blood disorders supported an asset indication prioritization strategy

How re-shaping an assets early value narrative towards the most impactful clinical scenarios streamlined its potential target indications and led to the next wave of funding

How a deep-dive analysis of pricing analogues informed the pricing strategy of a breakthrough advanced medicinal product in prostate cancer

How a deep understanding of the French IO landscape allowed for the development of core pricing scenarios to inform a client’s decision framework

Gain the deepest understanding of the data

How creating a unified vision and comprehensive framework for Real-World Evidence (RWE) supported seamless execution of RWE projects

How assessing the pricing and reimbursement risks associated with a product withdrawal supported the action steps to take in key Central and Eastern EU markets

How combining qualitative insights with survey outputs enabled deep understanding of payers’ preferences of the value a phase 3b multiple comparator study will bring in drug-resistant epilepsy

How a DELPHI survey informed the key inputs of a health economic model to support the launch of a breakthrough specialty product

How providing executive summaries of key diabetes studies & publications supported development of key marketing messages & promotional materials

Define the right value strategies

How building a step by step market access strategy created a pricing and value roadmap for a specialty product in a highly competitive and genericized market

How developing an early payer value story and value messages supported a differentiated offer within neurology, covering multiple possible scenarios at global and regional levels

How developing a HTA and pricing framework for orphan drugs across EU5 can help optimize portfolio expansion

How primary research of payers’ data needs and decision-making processes guided global market access activities

Operationalize the value

How focusing on the operational elements of pricing strategy supported in-country teams to strengthen their approach to pricing incremental innovation

How fostering close communications to prioritize key market access activities, ensured the timely delivery of optimized value materials for specialty assets

How a comprehensive review of the payer landscape is being used to support the development of a novel gene therapy

What we do

Who we are

Get started with Inbeeo and realise the true value of your assets.

Quick Access

Hours & Info